Scarica l'app Stockscreener
8.78
4.59%
0.395
Precedente Chiudi:
$8.385
Aprire:
$8.89
Volume 24 ore:
904.99K
Relative Volume:
0.24
Capitalizzazione di mercato:
$372.93M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-5.1953
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
-16.24%
1M Prestazione:
+27.29%
6M Prestazione:
+49.66%
1 anno Prestazione:
+392.70%
Intervallo 1D:
$8.37
$9.2091
Intervallo di 1 settimana:
$8.03
$13.68
Portata 52W:
$1.34
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.77 | 372.93M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.56 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.52 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
627.53 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
248.09 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
260.49 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Candel Therapeutics reports Phase 2 trial shows extended survival in Pancreatic Cancer - Proactive Investors USA
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive Investors UK
Candel stock plunges 20% following Phase 2 data release - MSN
Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data -February 25, 2025 at 01:36 pm EST - Marketscreener.com
Candel stock plunges 20% following Phase 2 data release (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Announces Positive Long-Term Survival Data From CAN-2409 Phase 2 Trial - Nasdaq
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy - Proactive Investors USA
Candel Therapeutics stock rises on positive trial data By Investing.com - Investing.com Australia
Candel Therapeutics stock rises on positive trial data - Investing.com
Candel Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Candel Therapeutics Reports Positive Final Survival Data for CAN-2409 in Borderline Resectable Pancreatic Cancer - Nasdaq
Candel Therapeutics Announces Positive Final Survival Data - GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - StockTitan
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - MSN
(CADL) Trading Report - Stock Traders Daily
Vontobel Holding Ltd. Sells 3,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Citigroup Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - Defense World
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Citi sets $25 target on Candel Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Decline in Short Interest - MarketBeat
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Candel Therapeutics Inc (CADL) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Candel Therapeutics: Entering Its Pivotal Year (NASDAQ:CADL) - Seeking Alpha
Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target -February 20, 2025 at 07:39 am EST - Marketscreener.com
Canaccord Genuity Group Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Citigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation - Nasdaq
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice - MSN
Citi sets $25 target on Candel Therapeutics stock with Buy rating - Investing.com India
Candel Therapeutics (NASDAQ:CADL) Now Covered by Analysts at Canaccord Genuity Group - Defense World
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoic - Asianet Newsable
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - Defense World
Analysts Say Candel Therapeutics Inc (NASDAQ: CADL) Should Remain On Your Watch List - Stocks Register
Trend Tracker for (CADL) - Stock Traders Daily
Insider Sale Alert: Candel Therapeutics Inc [CADL] – Is it Time to sell? - Knox Daily
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Bank of America - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns Buy Rating from Analysts at Bank of America - Defense World
Candel Therapeutics Inc (CADL) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Candel Therapeutics Inc (CADL) Stock: Evaluating the Annual Growth - The News Heater
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel initiated at buy by Citi, lead immunotherapy drugs cited - MSN
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
BofA Securities Initiates Candel Therapeutics at Buy With $15 Price Target -February 07, 2025 at 08:39 am EST - Marketscreener.com
B of A Securities Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation - Nasdaq
Nothing is Better Than Candel Therapeutics Inc (CADL) stock at the moment - SETE News
Candel Therapeutics Inc (CADL) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
A closer look at Candel Therapeutics Inc (CADL) is warranted - US Post News
Candel Therapeutics Inc (CADL) rating initates by H.C. Wainwright - Knox Daily
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):